Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.
Antiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth